Omeros Corporation (OMER)
| Market Cap | 884.44M |
| Revenue (ttm) | 71.34M |
| Net Income (ttm) | -144.12M |
| Shares Out | 61.93M |
| EPS (ttm) | -2.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 23 |
| Last Price | $14.19 |
| Previous Close | $14.24 |
| Change ($) | -0.05 |
| Change (%) | -0.35% |
| Day's Open | 14.36 |
| Day's Range | 13.95 - 14.38 |
| Day's Volume | 216,607 |
| 52-Week Range | 9.25 - 23.85 |
Omeros Corporation (NASDAQ: OMER) has announced the presentation of data on organ function improvement from its pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-assoc...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from its pivotal trial of narsoplimab for the treatment of hematopoietic stem cell tra...
Omeros (OMER) announces initial results from a phase I study of OMS906.
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the BofA 2021 Napa BioPharma Virtual C...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...
New York, New York--(Newsfile Corp. - June 5, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors are ad...
NEW YORK, June 1, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors are advised to conta...
Omeros (OMER) announces data on critically ill COVID-19 patients treated with lead candidate, narsoplimab.
New York, New York--(Newsfile Corp. - May 29, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER). Such investors are ad...
Omeros Corporation (NASDAQ: OMER) has announced preliminary results from the second cohort (n=10) of critically ill COVID-19 patients treated with narsoplimab in Bergamo, Italy. The patients were part o...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...
The FDA extends review period for Omeros' (OMER) BLA seeking approval of narsoplimab for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy. Stock down.
Omeros Corporation (NASDAQ: OMER) has revealed that the FDA needs additional time to review narsoplimab marketing application for hematopoietic stem cell transplant-associated thrombotic microangiopathy...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from Omeros' pivotal trial of narsoplimab for the treatment of hematopoietic stem cell...
Omeros (OMER) delivered earnings and revenue surprises of 1.96% and -5.74%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Omeros (NASDAQ:OMER) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 7.55% over the past year to ($0.57), which were in ...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2021, on Monday, May 10, 2021,...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the Centers for Disease Control and Prevention (CDC) has approved an International Classification of Diseases (ICD-10) di...
SEATTLE & SAN FRANCISCO--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) and Quantum Leap Healthcare Collaborative announced that dosing of patients with narsoplimab in the I-SPY COVID-19 Trial began...
Omeros (OMER) delivered earnings and revenue surprises of 15.63% and -41.76%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Omeros (NASDAQ:OMER) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 3.45% over the past year to ($0.60), which beat the esti...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its fourth quarter and year-end financial results for the period ended December 31, 2020, on Mond...
Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that Nadia Dac has joined Omeros as its Chief Commercial Officer. In this role, Ms. Dac will be responsible for all commercial...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced today that the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associate...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 39th Annual J.P. Morgan Healthcare ...
Omeros: A Ripening Fruit Ready To Pick
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced today that the Centers for Medicare & Medicaid Services (CMS) confirmed separate payment in ambulatory surgery centers (ASCs) for Om...
Omeros (OMER) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced that it has completed the rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FD...
Omeros Corp (OMER) CEO Greg Demopulos on Q3 2020 Results - Earnings Call Transcript
Omeros (OMER) delivered earnings and revenue surprises of 33.33% and 39.30%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the company will issue its third quarter financial results for the period ended September 30, 2020, on Monday, November 9...
Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) announced that results from its compassionate use study evaluating narsoplimab in COVID-19 patients in Italy will be shared during a virtual e...
The Omeros narsoplimab ship is finally coming in after long voyages in treacherous waters. Omeros' liquidity is improved but will likely remain challenging.
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced final data from its pivotal trial for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy ...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4th Complement-based Drug Development Summit. OMS906 is the company's lead human monoc...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the final results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated t...
OMER share price has been depressed over continued uncertainty regarding sales of their primary revenue-driver.
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today provided an update on the status of reimbursement for its cataract surgery drug OMIDRIA® (phenylephrine and ketorolac intraocular soluti...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that Gregory A. Demopulos, M.D.
Omeros (OMER) saw a big move last session, as its shares jumped 6% on the day, amid huge volumes.
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the Demy-Colton Virtual Salon Series featured an expert discussion of developments in the treatment of severe COVID-19. T...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation today announced that its Investigational New Drug Application (IND) to begin clinical trials with OMS906 has been cleared by the U.S. Food and Drug Administr...
About OMER
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HS... [Read more...]
| Industry Biotechnology | IPO Date Oct 8, 2009 |
| CEO Gregory Demopulos | Employees 277 |
| Stock Exchange NASDAQ | Ticker Symbol OMER |
Financial Performance
In 2020, Omeros's revenue was $73.81 million, a decrease of -33.98% compared to the previous year's $111.81 million. Losses were -$138.06 million, 63.4% more than in 2019.
Analyst Forecasts
According to 6 analysts, the average rating for Omeros stock is "Buy." The 12-month stock price forecast is 37.43, which is an increase of 163.78% from the latest price.